Diadia
Our TechnologyResearchResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

immunity · Mechanism Report

Can Parvovirus B19 IgM indicate recent infection despite discordant assays and a negative PCR?

Parvovirus B19 IgM can indicate recent infection, but discordant antibody assays and a negative blood PCR leave infection timing and current activity uncertain.

PlausibleOctober 1, 202610 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

Parvovirus B19 IgM can indicate recent infection, but discordant antibody assays and a negative blood PCR make the timing and current activity uncertain.

laying out figure…
1 of 4 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

The claim says IgM is compatible with a recent Parvovirus B19 infection, but it is not precise enough to date the infection on its own. The mechanism framing emphasizes that assay differences can create discordant antibody results, and that PCR may be negative after the early viremic phase even when infection was recent.

Verified conclusion

Parvovirus B19 testing is most informative when serology, PCR, symptoms, exposure timing, and immune status are interpreted together. In this 77-year-old man, an IgM result can support recent infection, but discordant antibody assays and negative blood PCR do not establish either a precise infection date or absence of recent/current infection.

Clinical interpretation

  • B19-specific IgM is a recognized marker compatible with recent infection, particularly when IgG is also positive. However, IgM may persist for up to approximately 6 months, so it cannot precisely date infection.
  • Isolated IgM positivity is less definitive: it may represent early infection, but nonspecific or cross-reactive reactivity can occur. Reported commercial-assay sensitivity ranges from 75.0% to 98.1% and specificity from 86.6% to 99.5%.
  • A negative blood PCR does not rule out a recent infection. In immunocompetent people, viremia is usually brief and declines as IgM appears; PCR may therefore be negative after the early viremic phase despite recently acquired infection.

Assay and biologic mechanisms

  • Discordant IgM results can reflect differences in assay design rather than a biologic change in infection status. VP1- versus VP2-based assays, and conformational versus denatured antigen presentation, can produce inconsistent or equivocal results.
  • Conversely, impaired humoral immunity can alter the expected relationship between antibodies and viremia, making immune status particularly relevant when interpreting PCR and serology.

Practical implications

  • Repeat or paired IgM/IgG testing in 1–2 weeks may clarify seroconversion or evolving antibody patterns. Where clinically indicated, quantitative PCR and/or IgG avidity testing can provide additional context.

Bottom line

  • The claim is supported: IgM can indicate recent B19 infection, but assay discordance plus negative blood PCR leaves timing and current viral activity indeterminate rather than resolved.

References

  1. CLINICAL PRACTICE GUIDELINE — hse.ie ↗
  2. PARVS - Overview: Parvovirus B19 Antibodies, IgG and IgM, Serum — mayocliniclabs.com ↗
  3. Evaluation of Diagnostic Accuracy of Eight Commercial ... — pmc.ncbi.nlm.nih.gov ↗
  4. Comparison of a Baculovirus-Based VP2 Enzyme Immunoassay (EIA) to an Escherichia coli-Based VP1 EIA for Detection of Human Parvovirus B19 Immunoglobulin M and Immunoglobulin G in Sera of Pregnant Women | Journal of Clinical Microbiology — journals.asm.org ↗
  5. Identification of Past and Recent Parvovirus B19 Infection ... — pmc.ncbi.nlm.nih.gov ↗
  6. Prenatal parvovirus B19 infection - PMC - NIH — pmc.ncbi.nlm.nih.gov ↗
  7. Human Parvovirus B19 and blood product safety - PMC - NIH — pmc.ncbi.nlm.nih.gov ↗
  8. Human parvovirus B19: general considerations and impact on ... — academic.oup.com ↗
  9. Clinical Presentations of Parvovirus B19 Infection | AFP — aafp.org ↗
  10. Evaluation of five commercial tests for detection of immunoglobulin M antibodies to human parvovirus B19 — journals.asm.org ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Plausible14 sourcesCan suboptimal vitamin D reduce immune regulation?→Plausible8 sourcesIs food allergy an immune reaction distinct from the TMAO pathway?→